ABIVAX (EPA:ABVX) | WebDisclosure

Basculer en Français

9784	Companies
196003	Keywords
127059	Articles
104235	Press releases

Home
Companies
ABIVAX

PRESS RELEASE

published on 07/25/2025 at 08:00, 6 months 8 days ago

Abivax annonce l’exercice intégral de l’option de souscription d’ADS supplémentaires des teneurs de livre associés, portant le produit brut de l'Offre à 747,5 M$ (637,5 M€)
Abivax annonce exercice intégral option souscription ADS supplémentaires. Produit brut Offre à 747,5 M$. Société biotechnologie spécialisée en immunothérapie. Prix offre 64,00$ par ADS. Actions admises Nasdaq et Euronext. Document relatif déposé auprès de la SEC

Biotechnologie Abivax SEC Immunothérapie Prix Offre
PRESS RELEASE

published on 07/25/2025 at 08:00, 6 months 8 days ago

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
Abivax announces full exercise of underwriters’ option to purchase additional ADSs, bringing gross proceeds of offering to $747.5M (€637.5M). Company to apply net proceeds to identified use of funds

Abivax Underwriters ADSs Offering Proceeds
PRESS RELEASE

published on 07/25/2025 at 08:00, 6 months 8 days ago

Abivax annonce l’exercice intégral de l’option de souscription d’ADS supplémentaires des teneurs de livre associés, portant le produit brut de l'Offre à 747,5 M$ (637,5 M€)
Abivax a exercé intégralement l’option de souscription d’ADS supplémentaires, portant le produit brut de l'Offre à 747,5 M$ (637,5 M€), soutenant le développement de thérapies pour maladies inflammatoires

Biotechnologie Abivax Maladies Inflammatoires Souscription Produit Brut
BRIEF

published on 07/24/2025 at 14:45, 6 months 9 days ago

Abivax's $650M Public Offering of ADS

Biotechnology Abivax Capital Increase Public Offering Ads
BRIEF

published on 07/24/2025 at 14:45, 6 months 9 days ago

Abivax lance une offre publique d'ADS de 650 millions de dollars

Biotechnologie Abivax Augmentation De Capital Offre Publique PUBLICITÉS
PRESS RELEASE

published on 07/24/2025 at 14:40, 6 months 9 days ago

Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris
Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris. La société de biotechnologie se concentre sur le développement de traitements thérapeutiques pour les maladies inflammatoires chroniques

Euronext Paris Biotechnologie Abivax Traitements Thérapeutiques Maladies Inflammatoires
PRESS RELEASE

published on 07/24/2025 at 14:40, 6 months 9 days ago

Abivax annonce les modalités définitives de l’offre au public de 650M$ (554M€) d’American Depositary Shares
Abivax annonce les modalités définitives de l’offre au public de 650M$ (554M€) d’American Depositary Shares pour financer le développement de thérapies biotechnologiques. Details de l'offre, stabilisation et prévisions financières

Biotechnologie Abivax Ads Offre Publique Modalités Définitives
PRESS RELEASE

published on 07/24/2025 at 14:40, 6 months 9 days ago

Abivax announces trading resumption of its ordinary shares on Euronext Paris
Abivax announces the trading resumption of its ordinary shares on Euronext Paris after a temporary halt for a public offering confirmation and pricing announcement

Euronext Paris Abivax Public Offering Clinical-stage Biotechnology Trading Resumption
PRESS RELEASE

published on 07/24/2025 at 14:40, 6 months 9 days ago

Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris
Abivax annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris. La société de biotechnologie se concentre sur le développement de traitements pour les maladies inflammatoires chroniques

Euronext Paris Biotechnologie Abivax Négociations Traitements
PRESS RELEASE

published on 07/24/2025 at 14:40, 6 months 9 days ago

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
Abivax announces pricing of $650M (€554M) public offering of American Depositary Shares to fund clinical development and working capital, with expected closing on July 28, 2025

Abivax Clinical Development Public Offering Pricing Closing

Accesswire

Published on 02/02/2026 at 22:05, 1 hour 24 minutes ago

Organto Foods to Attend Fruit Logistica 2026 in Berlin, Germany From February 4-6, 2026
Published on 02/02/2026 at 15:00, 8 hours 29 minutes ago

Jericho Energy Ventures Strategically Terminates SmartKem LOI to Advance Independent Data Center Energy Infrastructure Platform
Published on 02/02/2026 at 14:30, 8 hours 59 minutes ago

Unusual Machines Promotes Drew Camden to President
Published on 02/02/2026 at 14:30, 8 hours 59 minutes ago

Predictiv AI Provides Pilot Update from Innovate Calgary's Soaring Higher Challenge with Calgary Airports and WestJet
Published on 02/02/2026 at 14:30, 8 hours 59 minutes ago

NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres

View all ACCESSWIRE

EQS Group

Published on 02/02/2026 at 20:00, 3 hours 29 minutes ago

CGTN AMERICA & CCTV UN: Cultural Event Celebrating the Spring Festival and the 55th Anniversary of China-U.S. Ping-Pong Diplomacy
Published on 02/02/2026 at 19:57, 3 hours 32 minutes ago

US federal court grants preliminary injunction allowing Sunrise Wind construction to resume
Published on 02/02/2026 at 19:42, 3 hours 46 minutes ago

EQS-Adhoc: ProSiebenSat.1 publishes preliminary figures for financial year 2025
Published on 02/02/2026 at 19:05, 4 hours 24 minutes ago

Virtual Science AI launches the life science industry's first medical congress AI solution for real-time event conversational intelligence
Published on 02/02/2026 at 19:00, 4 hours 29 minutes ago

PATRIMOINE ET COMMERCE: INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF

Les Echos

Published on 02/02/2026 at 18:23, 5 hours 6 minutes ago

Monthly disclosure of the total number of shares and voting rights - January 2026
Published on 02/02/2026 at 18:23, 5 hours 6 minutes ago

TF1 - Déclaration mensuelle des actions et droits de vote - Janvier 2026
Published on 02/02/2026 at 18:00, 5 hours 29 minutes ago

Covivio - Information on total number of voting rights and share capital
Published on 02/02/2026 at 18:00, 5 hours 29 minutes ago

Covivio Hotels - Informations relatives au nombre total de droits de vote et d’actions composant le capital social
Published on 02/02/2026 at 18:00, 5 hours 29 minutes ago

Covivio - Informations relatives au nombre total de droits de vote et d’actions composant le capital social

View all LES ECHOS COMFI WIRE